Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF)
Last Updated: Tuesday, February 9, 2021
According to long-term safety and tolerability data presented at the 2020 ASH Annual Meeting from a phase I/II extension study, > 24 cycles of fedratinib was well-tolerated among patients with intermediate- or high-risk myelofibrosis. Any-grade treatment-related adverse events were reported in < 25% patients, with the most common being thrombocytopenia, fatigue, nausea, diarrhea, and vomiting.
Advertisement
News & Literature Highlights
